News

• US generics launch and approval for Dr Reddy’s and Lupin
• Five Chinese companies join UN’s MPP for Covid-19 medicines
• South Korean companies to make generic Bridion and COVID-19 drugs
• Revlimid (lenalidomide) generics launch across Europe

Research

• Evaluation of pharmaceutical equivalency of manufactured generic drugs in UAE
• New insights into the amount of R & D for new uses of generic drugs
• Pricing and reimbursement of medicines in Canada
• Medicines pricing conditions in Italy and Brazil: comparison of regulations

General

• FDA releases one-year progress report for the Generic Drug Cluster
• Pharmaceutical manufacturing companies in Brazil
• Pharmaceutical companies in Argentina
• Pharmaceutical companies in Latin America and the Caribbean

News

• EMA recommends approval of eculizumab biosimilar Bekemv
• China approves tocilizumab copy biological BAT1806
• FDA accepts application for denosumab biosimilar GP2411
• EMA accepts application for ustekinumab biosimilar AVT04

Research

• Low biosimilar uptake in regions of low social and political trust
• A global overview of manufacturers of follow-on biologicals
• Study supports increased development of insulin biosimilars
• Malaysian hospital pharmacists’ perspective on and role in promoting biosimilars use

General

• Lilly, Novo Nordisk and Sanofi slash prices of insulin in the US
• American College of Rheumatology position statement on biosimilars updated
• Biosimilars approved in Canada
• US PBMs add multiple Humira biosimilars to formularies

• Latin American Forum
• Non‐Biological Complex Drugs
• Country Focus

• Guidelines
• Policies & Legislation
• Reports

• Conferences
• Sponsored Articles
• Sponsored Links